PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 10, 20250 citationsOpen Access

Supplementary Figure 2 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

View Full Paper
MUMireia Uribe‐HerranzAOAina Oliver‐CaldésNMNeus Martínez-Micaelo

Key Points

  • Alterations in gut microbiota may correlate with immune responses in CAR-T therapy for myeloma patients.
  • Taxonomic profiles exhibit significant differences in relative abundances before and after lymphodepletion.
  • The analysis focuses on apheresis umbilical microbiota to unveil taxonomic compositions affecting therapy outcomes.
  • Findings highlight the necessity of considering microbiota profiles during CAR-T therapy in myeloma cases.

Abstract

Supplementary Figure S2 illustrates the pre-CAR T-cell infusion gut microbiota taxonomic profiles in multiple myeloma patients, specifically detailing order and family-level compositions at apheresis and before lymphodepletion, along with comparisons of relative mean abundances between these time points.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Uribe‐Herranz et al. (2025) studied this question.

synapsesocial.com/papers/68c187339b7b07f3a0611aebhttps://doi.org/10.1158/2643-3230.30040897
Ask AI
Helpful
Bookmark
Share
View Full Paper